Peter Chei-Way Pan1, Aya Haggiagi2. 1. Division of Neuro-Oncology, Columbia University Irving Medical Center, 710 W 168th St, 9th Floor, New York, NY, 10032, USA. 2. Division of Neuro-Oncology, Columbia University Irving Medical Center, 710 W 168th St, 9th Floor, New York, NY, 10032, USA. amh2237@cumc.columbia.edu.
Abstract
PURPOSE OF REVIEW: This review highlights the spectrum of neurologic adverse events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the treatments undertaken, and the clinical outcomes. RECENT FINDINGS: The advent of ICIs has revolutionized cancer therapy. Neurologic adverse events (NAEs) are rare but clinically significant complication of ICIs. They can involve both the central and peripheral nervous system. Examples include myositis, neuropathy, encephalopathy, and myasthenia gravis. Treatment consists of holding the ICI, administration of corticosteroids, and other immunomodulatory agents as needed. The outcomes are generally favorable; however, rarely severe events can lead to significant morbidity and even mortality. Identifying and treating the range of neurologic adverse events that may potentially arise with ICIs is very important as the oncologic indications for their use continues to expand.
PURPOSE OF REVIEW: This review highlights the spectrum of neurologic adverse events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the treatments undertaken, and the clinical outcomes. RECENT FINDINGS: The advent of ICIs has revolutionized cancer therapy. Neurologic adverse events (NAEs) are rare but clinically significant complication of ICIs. They can involve both the central and peripheral nervous system. Examples include myositis, neuropathy, encephalopathy, and myasthenia gravis. Treatment consists of holding the ICI, administration of corticosteroids, and other immunomodulatory agents as needed. The outcomes are generally favorable; however, rarely severe events can lead to significant morbidity and even mortality. Identifying and treating the range of neurologic adverse events that may potentially arise with ICIs is very important as the oncologic indications for their use continues to expand.
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: A Taliansky; O Furman; M Gadot; D Urban; J Bar; R Shapira-Frumer; B Kaufman; N Asher; R Leibowitz-Amit; A Itay Journal: Support Care Cancer Date: 2021-06-12 Impact factor: 3.603
Authors: LeAnne Young; Shanda Finnigan; Howard Streicher; Helen X Chen; James Murray; H Nida Sen; Elad Sharon Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751
Authors: Bart K Chwalisz; James Hillis; Amanda C Guidon; Leeann B Burton; Teilo H Schaller; Anthony A Amato; Allison Betof Warner; Priscilla K Brastianos; Tracey A Cho; Stacey L Clardy; Justine V Cohen; Jorg Dietrich; Michael Dougan; Christopher T Doughty; Divyanshu Dubey; Jeffrey M Gelfand; Jeffrey T Guptill; Douglas B Johnson; Vern C Juel; Robert Kadish; Noah Kolb; Nicole R LeBoeuf; Jenny Linnoila; Andrew L Mammen; Maria Martinez-Lage; Meghan J Mooradian; Jarushka Naidoo; Tomas G Neilan; David A Reardon; Krista M Rubin; Bianca D Santomasso; Ryan J Sullivan; Nancy Wang; Karin Woodman; Leyre Zubiri; William C Louv; Kerry L Reynolds Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751